Cervical verrucous carcinoma

Summary

Cervical verrucous carcinoma (MONDO:0002761) is a cancer. A subtype of verrucous carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cervical verrucous carcinoma
Mondo ID	MONDO:0002761
DOID	DOID:3743
NCIT	C40190
UMLS	C1516435
MedGen	275713
GARD	0023237
Anatomy (UBERON)	UBERON:0000002
Is cancer (heuristic)	yes

Also known as: cervical verrucous carcinoma · uterine cervix verrucous carcinoma

Disease family

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › papillary squamous carcinoma › verrucous carcinoma › cervical verrucous carcinoma

Related subtypes (9): vulva verrucous carcinoma, bladder verrucous carcinoma, esophagus verrucous carcinoma, urethral verrucous carcinoma, plantar verrucous skin carcinoma, larynx verrucous carcinoma, penis verrucous carcinoma, verrucous carcinoma of oral cavity, Buschke Lowenstein tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.